Objective:

To develop a drug-regulated off-switch for CAR-T cells using venetoclax, enhancing control over CAR activation and improving patient safety.

Key Findings:

• Venetoclax induced near-total receptor disassembly in DROP-CAR T cells after 24 hours, with a half-maximal inhibitory concentration of 59 nM.
• DROP-CAR T cells showed reduced interferon-γ production and cytotoxicity when treated with venetoclax, indicating a significant impact on T cell functionality.
• Live-cell imaging revealed disruption of immune synapse formation and altered calcium flux in DROP-CAR T cells, underscoring the mechanism of action.

Interpretation:

The DROP-CAR system allows for reversible control of CAR-T cell activation using a clinically approved drug, enhancing safety and flexibility in cancer therapy.

Limitations:

• The study was conducted in vitro and in a limited animal model, which may not fully represent human responses; specifically, the model used was [insert specific model].
• Further research is needed to evaluate long-term effects and efficacy in diverse tumor types to ensure broad applicability.

Conclusion:

This research presents a novel approach to modulate CAR-T cell activity using venetoclax, potentially improving therapeutic strategies in cancer treatment and enhancing patient safety.